Treatment Helps Sex Stage A Comeback After Menopause

Sexual pain at this stage in a woman’s life is usually the result of the typical drying and thinning of tissues in and around the vagina after menopause, called vulvovaginal atrophy (VVA), coupled with a decrease in sexual activity. Vaginal lubricants and moisturizers, vaginal estrogen, and ospemifene, a recently approved oral drug that is a selective estrogen receptor modulator (SERM), can all be used to treat it.

Known as Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER), the survey was commissioned by Novo Nordisk, the maker of a vaginal estrogen treatment. It included postmenopausal women volunteers age 55 to 65 who had VVA and their male partners. This part of CLOSER looked at how treatment with vaginal estrogen affected their sex lives.

Before treatment, a majority of these women (58%) said they had been avoiding intimacy because of the pain, and 68% said they had lost their desire because of it. An even higher percentage of the men (78%) thought their partner’s vaginal discomfort caused them to avoid intimacy. About a third of the men and women had stopped having sex altogether.

After treatment, a majority of women and men reported sex was less painful for them and their partner, and more than 40% of the women and men said sex was more satisfying. Twenty-nine percent of the women and 34% of the men said their sex life had improved. Treatment also had a positive impact on the women’s self esteem. About a third felt more optimistic about the future of their sex life, and a similar number felt more connected to their partners.

“There is no need for a woman’s quality of life to decline because of VVA,” said NAMS Executive Director Margery L.S. Gass, MD.

Many women get relief with vaginal lubricants and moisturizers and regular sexual activity or the use of vaginal dilators. Vaginal estrogen, in the form of creams, tablets, or rings, is a common therapy and is appealing for women who cannot or choose not to take oral hormones, since absorption into the bloodstream is minimal. Women who have had breast or uterine cancer are encouraged to discuss the pros and cons of different treatments with their oncologist. The SERM offers an alternative for women who choose not to use any oral or vaginal hormone therapy.

The article, “Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners,” will be published in the February 2014 print edition of Menopause.

Founded in 1989, The North American Menopause Society (NAMS) is North America’s leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field—including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit our website:http://www.menopause.org

Contacts and sources:
Eileen Petridis